Association between the FAS rs2234767G/A polymorphism and cancer risk: A systematic review and meta-analysis

DNA and Cell Biology

Volumn 33, Issue 5, 2014, Pages 320-327

  Wang, Xin ^a   Xing, Guo Hong ^a   Fan, Chang Chun ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

BLADDER CANCER; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COLORECTAL CANCER; ESOPHAGUS CANCER; ETHNICITY; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; KIDNEY CARCINOMA; LARYNX CARCINOMA; LEUKEMIA; LUNG CANCER; MELANOMA; META ANALYSIS (TOPIC); MOUTH SQUAMOUS CELL CARCINOMA; NASOPHARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OVARY CARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SALIVARY GLAND CARCINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; SYSTEMATIC REVIEW; THYROID CARCINOMA; UTERINE CERVIX CANCER;

ANTIGENS, CD95; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84899769389     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2013.2273     Document Type: Review

References (66)

1. Aguilar-Reina, J., Ruiz-Ferrer, M., Pizarro, M.A., et al. (2005). The -670A >G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C. J Viral Hepat 12, 568-573.
2. Bennett, M.W., O'Connell, J., O'Sullivan, G.C., et al. (1998). The Fas counterattack in vivo: apoptotic depletion of tumorinfiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160, 5669-5675.
3. Cao, Y., Miao, X.P., Huang, M.Y., et al. (2010). Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol Carcinog 49, 944-950.
4. Chen, X.B., Chen, G.L., Liu, J.N., et al. (2009). Genetic polymorphisms in STK15 and MMP-2 associated susceptibility to esophageal cancer in Mongolian population. Chin J Pre Med 43, 559-564.
5. Crew, K.D., Gammon, M.D., Terry, M.B., Zhang, F.F., et al. (2007). Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 28, 2548-2551.
6. Danial, N.N., and Korsmeyer, S.J. (2004). Cell death: critical control points. Cell 116, 205-219.
7. DerSimonian, R., and Laird, N. (1986). Meta-analysis in clinical trials. Control Clin Trials 7, 177-188.
8. Dong, L.M., Potter, J.D., White, E., et al. (2008). Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299, 2423-2436.
9. Evan, G.I., and Vousden, K.H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348.
10. Gastman, B.R., Atarshi, Y., Reichert, T.E., et al. (1999). Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59, 5356-5364.
11. Gormus, U., Ergen, A., Yaylim-Eraltan, I., et al. (2007a). Fas- 1377 A/G polymorphism in lung cancer. In Vivo 21, 663-666.
12. Gormus, U., Ergen, A., Yilmaz, H., et al. (2007b). Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res 27, 991-994.
13. Harismendy, O., and Frazer, K.A. (2009). Elucidating the role of 8q24 in colorectal cancer. Nat Genet 41, 868-869.
14. Hashemi, M., Fazaeli, A., Ghavami, S., et al. (2013). Functional polymorphisms of FAS and FASL gene and risk of breast cancer-pilot study of 134 cases. PLoS One 8, e53075.
15. Hayashino, Y., Noguchi, Y., and Fukui, T. (2005). Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 15, 235-243.
16. Ho, T., Li, G., Zhao, C., et al. (2008). Fas single nucleotide polymorphisms and risk of thyroid and salivary gland carcinomas: a case-control analysis. Head Neck 30, 297-305.
17. Hsu, P.I., Lu, P.J., Wang, E.M., et al. (2008). Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. Anticancer Res 28, 97-103.
18. Jung, Y.J., Kim, Y.J., Kim, L.H., et al. (2007). Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection. Intervirology 50, 369-376.
19. Kang, S., Dong, S.M., Seo, S.S., et al. (2008). FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 180, 1-5.
20. Kim, H.J., Jin, X.M., Kim, H.N., et al. (2010). Fas and FasL polymorphisms are not associated with acute myeloid leukemia risk in Koreans. DNA Cell Biol 29, 619-624.
21. Koshkina, N.V., Kleinerman, E.S., Li, G., et al. (2007). Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatr Hematol Oncol 29, 815-821.
22. Kupcinskas, J., Wex, T., Bornschein, J., et al. (2011). Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet 12, 112.
23. Lai, H.C., Lin, W.Y., Lin, Y.W., et al. (2005). Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol 99, 113-118.
24. Lee, S.H., Shin, M.S., Park, W.S., et al. (1999). Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 18, 3754-3760.
25. Li, C., Larson, D., Zhang, Z., et al. (2006a). Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 16, 253-263.
26. Li, C., Wu, W., Liu, J., et al. (2006b). Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a casecontrol analysis. Pharmacogenet Genomics 16, 245-251.
27. Li, H., Guo, H.Y., Sun, T., et al. (2009). Association between Fas/Fas L gene promoter polymorphisms and pathogenic risk of cervical cancer (Chinese). Chin J Oncol 31, 38-41.
28. Li, T.F., Ren, K.W., and Liu, P.F. (2012). Meta-analysis of epidermal growth factor polymorphisms and cancer risk: involving 9,779 cases and 15,932 controls. DNA Cell Biol 31, 568-574.
29. Li, Y., Hao, Y.L., Kang, S., et al. (2013). Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Gynecol Oncol 128, 584-589.
30. Lowe, S.W., and Lin, A.W. (2000). Apoptosis in cancer. Carcinogenesis 21, 485-495.
31. Mandal, R.K., and Mittal, R.D. (2012). Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population? Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population? Urol Oncol 30, 555-561.
32. Mantel, N., and Haenszel, W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22, 719-748.
33. Müschen, M., Warskulat, U., and Beckmann, M.W. (2000). Defining CD95 as a tumor suppressor gene. J Mol Med (Berl) 78, 312-325.
34. Nagata, S., and Golstein, P. (1995). The Fas death factor. Science 267, 1449-1456.
35. Park, S.H., Choi, J.E., Kim, E.J., et al. (2006). Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 54, 303-308.
36. Pharoah, P.D., Dunning, A.M., Ponder, B.A., et al. (2004). Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4, 850-860.
37. Qiu, L.X., Shi, J., Yuan, H., et al. (2009). FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum Genet 125, 431-435.
38. Qureshi, A., Nan, H., Dyer, M., et al. (2010). Polymorphisms of FAS and FAS ligand genes and risk of skin cancer. J Dermatol Sci 58, 78-80.
39. Reichmann, E. (2002). The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 12, 309-315.
40. Shao, P., Ding, Q., Qin, C., et al. (2011). Functional polymorphisms in cell death pathway genes FAS and FAS ligand and risk of prostate cancer in a Chinese population. Prostate 71, 1122-1130.
41. Sibley, K., Rollinson, S., Allan, J.M., et al. (2003). Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63, 4327-4330.
42. Sun, T., Miao, X., Zhang, X., et al. (2004). Polymorphisms of death pathway genes FAS nd FASL in esophageal squamouscell carcinoma. J Natl Cancer Inst 96, 1030-1036.
43. Sun, T., Zhou, Y., Li, H., et al. (2005). FASL-844Cpolymorphismis associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 202, 967-974.
44. Ter-Minassian, M., Zhai, R., Asomaning, K., et al. (2008). Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 29, 2147-2152.
45. Tong, N., Zhang, L., Sheng, X., et al. (2012). Functional polymorphisms in FAS, FASL and CASP8 genes and risk of childhood acute lymphoblastic leukemia: a case-control study. Leuk Lymphoma 53, 1360-1366.
46. Ueda, M., Terai, Y., Kanda, K., et al. (2006). Fas gene promoter -670 polymorphism in gynecological cancer. Int J Gynecol Cancer 16 Suppl 1, 179-182.
47. Viard-Leveugle, I., Veyrenc, S., French, L.E., et al. (2003). Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 201, 268-277.
48. Wang, J., Gao, J., Li, Y., et al. (2013). Functional polymorphisms in FAS and FASL contribute to risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. Gene 524, 193-196.
49. Wang, L.H., Ting, S.C., Chen, C.H., et al. (2010). Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population. J Oral Pathol Med 39, 155-161.
50. Wang, M., Wu, D., Tan, M., et al. (2009). FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet 47, 559-568.
51. Wang, W., Zheng, Z., Yu, W., et al. (2012). Polymorphisms of the FAS and FASL genes and risk of breast cancer. Oncol Lett 3, 625-628.
52. Wokolorczyk, D., Gliniewicz, B., Sikorski, A., et al. (2008). A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res 68, 9982-9986.
53. World Health Organization. (2008). The Global Burden of Disease: 2004 Update. Geneva: World Health Prganization.
54. Yang, M., Sun, T., Wang, L., et al. (2008). Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 14, 3230-3236.
55. Yang, S., Miao, X.P., Zhang, X.M., et al. (2005). Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer (Chinese). NatlMed J China 85, 2132-2135.
56. Zhang, B., Sun, T., Xue, L., et al. (2007a). Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28, 1067-1073.
57. Zhang, H., Sun, X.F., Synnerstad, I., et al. (2007b). Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J 13, 233-237.
58. Zhang, M.J., Liu, C.H., Wang, W.Q., et al. (2010). Aossociation between Fas -1377 gene polymorphism and susceptibility of gastric cancer (Chinese). Shan Dong Yin Yao 50, 36-37.
59. Zhang, W., Li, C., Wang, J., et al. (2012). Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma. Hepatogastroenterology 59, 141-146.
60. Zhang, X., Miao, X., Sun, T., et al. (2005). Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 42, 479-484.
61. Zhang, Z., Wang, L.E., Sturgis, E.M., et al. (2006). Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12, 5596-5602.
62. Zhang, Z., Xue, H., Gong, W., et al. (2009). FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 30, 487-493.
63. Zhou, R.M., Wang, N., Chen, Z.F., et al. (2010a). Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol 25, 555-561.
64. Zhou, R.M., Wang, N., Sun, D.L., et al. (2010b). Correlation of polymorphism in apoptosis-associated genes FAS and FASL to the risk of gastric cardiac adenocarcinoma (Chinese). Chin J Cancer Prev Treat 17, 1609-1622.
65. Zhu, J., Qin, C., Wang, M., Yan, F., et al. (2010). Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma. Mol Carcinog 49, 810-817.
66. Zintzaras, E. (2010). The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Stat Appl Genet Mol Biol 9, Article21.